Saccharomyces boulardii per Clostridioides difficile Infection (CDI)

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

In sintesi

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

Key Study Findings

Review

The evidence for probiotics in the treatment of digestive disorders in the pediatric population.

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: Pediatric population

Review

Clostridioides difficile Infections: Prevention and Treatment Strategies.

Dose: None vs: None Outcome: C. difficile infection treatment outcomes Effetto: None None

Popolazione: Patients with C. difficile infection

Review 520 weeks

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Review

Clostridium difficile Colitis Prevention and Treatment.

Dose: None vs: None Outcome: Diarrhea outcomes Effetto: None None

Popolazione: None

Systematic Review n=228

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

Dose: None vs: None Outcome: Diarrhea outcomes Effetto: None None

Popolazione: None

Review

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?

Dose: None vs: None Outcome: GI condition outcomes (C. diff, AAD, H. pylori) Effetto: None None

Popolazione: Adults with GI conditions

Key Statistics

Studi

3000

Partecipanti

↑

Positive

Grado

Referenced Papers

The evidence for probiotics in the treatment of digestive disorders in the pediatric population. Review

Journal of gastroenterology … 2025 10 citazioni

Clostridioides difficile Infections: Prevention and Treatment Strategies. Review

Advances in experimental … 2024 2 citazioni

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. Review

Cureus 2023 5 citazioni

Clostridium difficile Colitis Prevention and Treatment. Review

Advances in experimental … 2019 17 citazioni

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Other

Frontiers in medicine 2018 450 citazioni

Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Review

Pharmacological research 2018 132 citazioni

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Review

The American journal … 2018 46 citazioni

Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. Review

World journal of … 2017 68 citazioni

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Meta-Analysis

Journal of pediatric … 2016 233 citazioni

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Review

Clinical and experimental … 2016 82 citazioni

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Other

Open forum infectious … 2016 58 citazioni

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Review

Antibiotics (Basel, Switzerland) 2015 104 citazioni

Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Review

Nutrition in clinical … 2015 31 citazioni

Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. RCT

The American journal … 2012 104 citazioni

Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. Other

The American journal … 2012 5 citazioni

Probiotics for prevention and treatment of diarrhea. Review

Journal of clinical … 2011 432 citazioni

Probiotics. Review

American journal of … 2010

Probiotics as prevention and treatment for diarrhea. Review

Current opinion in … 2009 82 citazioni

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Meta-Analysis

The American journal … 2006 918 citazioni

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Review

Journal of clinical … 2006 112 citazioni

Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. RCT

Medical science monitor … 2006

Protection from gastrointestinal diseases with the use of probiotics. Review

The American journal … 2001 648 citazioni

Treatment and prevention of antibiotic associated diarrhea. Review

International journal of … 2000 181 citazioni

Mechanisms and management of antibiotic-associated diarrhea. Review

Clinical infectious diseases … 1998 346 citazioni

Pharmaceutical probiotics for the treatment of anaerobic and other infections. Other

Anaerobe 1997 40 citazioni

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. CCT

Gastroenterology 1989 418 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:: 250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:: 500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:: 500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:: 250-500 mg/day starting 5 days before travel

Limite massimo: Well-tolerated up to 1,000 mg/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio	Durata	Effetto	N
None	--	Mixed	--
None	--	Positive	--
None	520 weeks	Positive	--
None	--	Mixed	--
None	--	Mixed	228
None	--	Mixed	--
None	--	Mixed	--
None	--	Mixed	--

Momento migliore per l'assunzione: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Effetti collaterali segnalati

⚠ Mild gas and bloating
⚠ Rare: fungemia in critically ill patients with central venous catheters
⚠ Thirst (yeast may increase water requirements)
⚠ Very rare: potential environmental contamination risk in ICU settings

Interazioni note

● Antifungal medications (may kill S. boulardii, reducing effectiveness)
● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Livello di assunzione massimo tollerabile: Well-tolerated up to 1,000 mg/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Saccharomyces boulardii help with Clostridioides difficile Infection (CDI)?

Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Clostridioides difficile Infection (CDI) management. Our evidence grade is B (Good Evidence).

How much Saccharomyces boulardii should I take for Clostridioides difficile Infection (CDI)?

Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Saccharomyces boulardii?

Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Saccharomyces boulardii and Clostridioides difficile Infection (CDI)?

We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

Related Evidence

Saccharomyces boulardii per altre condizioni

Antibiotic-Associated Diarrhea (AAD) A Traveler's Diarrhea B

Verdetto rapido

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

Evidence Strength72%

High confidence

Analisi degli studi

RCT (2)Meta (2)Other (2)

Confronta le alternative

Scoprite come si confrontano altri ingredienti per questa condizione.

Visualizza tutti gli ingredienti per Clostridioides difficile Infection (CDI)

Approfondimenti

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.